Inflammation Research

, Volume 45, Issue 5, pp 234–238 | Cite as

Decrease of ciliary beat frequency by platelet activating factor: Protective effect of ketotifen

  • L. Kahhak
  • A. Roche
  • C. Dubray
  • C. Arnoux
  • J. Benveniste
Original Research Papers

Abstract

The ciliary beat frequency (CBF) of the tracheal epithelial cells controls in part the respiratory tract mucociliary transport efficiency. We investigated the effects on CBF of PAF-acether (PAF) and its metabolite/precursor lyso-PAF. Guinea-pig tracheal rings were incubated for 3 to 6 h with 1 μM PAF (C16, C18, C16/C18: 80/20%), lyso-PAF C16 or lyso-phosphatidylcholine (LPC). CBF changes were assessed by microphotooscillography (mean number of measures per ring=14). We also examined the effect on PAF-induced CBF changes of the PAF receptor-antagonist WEB 2086, the anti-asthmatic/anti-anaphylactic drug ketotifen and the anti-histamine H1 pyribenzamine. CBF of control rings exposed to vehicle only from 0 to 6 h showed no significant statistical variations (hertz, mean±SEM): 10.8±0.1 (n of measures=890). By contrast, 1 μM C16, C18, and C16/C18 PAF significantly inhibited CBF after 3 to 6h incubation. C16 and C16/C18 PAF were more potent than C18 PAF (8.8±0.2, n=112, 8.7±0.2, n=64, and 9.6±0.1, n=537 respectively; ANOVA analysis, p<0.001 from control). At the same concentration, lyso-PAF also inhibited CBF, 9.5±0.1 (n=197, p<0.001) but not LPC, 10.5±0.2 (n=127). WEB 2086 inhibited lyso-PAF and C16/18 PAF-induced CBF decrease. Preincubation (20 min) with ketotifen but not with pyribenzamine (1 μM) also suppressed the CBF inhibitory effect of PAF and lyso-PAF. Incubation of [3H]PAF with tracheal rings from 10 min to 6 h resulted in its partial metabolism (25%) into [3H]lyso-PAF and a compound with a short retention time (10 min). [3H]lyso-PAF incubated for 3 h with tracheal rings was partially metabolized (10%) into [3H]PAF and a compound with a short retention time. The PAF-induced decrease of CBF is congruent with its influence on pulmonary clearance, possibly via a specific receptor, since WEB 2086 abolished the effect of PAF. The inhibition of the PAF-induced CBF decrease by ketotifen may contribute to the therapeutic properties of this antiallergic drug.

Key words

Ciliary beat frequency Platelet activating factor Ketotifen PAF-antagonist Anti-histamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Lucas A, Douglas LC. Principles underlying ciliary activity in the respiratory tract. Otolaryngol 1934;20:518–41.Google Scholar
  2. [2]
    Hiding AC. Ciliary streaming in the lower respiratory tract. Am J Pathol 1957;191:404–10.Google Scholar
  3. [3]
    Sturges JM. Mucociliary clearance and mucous secretion in the Lung. In: Witschi HP, Brain JD, editors. Toxicology of Inhaled Materials. Berlin: Springer-Verlag, 1985:319–67.Google Scholar
  4. [4]
    Seybold ZV, Mariassy AT, Stroh D, Kim CS, Gazeroglu H, Wanner A. Mucociliary interaction in vitro: effects of physiological and inflammatory stimuli. J Appl Physiol 1990;68: 1421–6.CrossRefPubMedGoogle Scholar
  5. [5]
    Laitinen LA, Heino A, Laitinen T, Kava T, Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Resp Dis 1985;131:599–606.PubMedGoogle Scholar
  6. [6]
    Dulfano MJ, Luck CK, Beckage M, Wooten O. Ciliary inhibitory effects of asthma patients sputum. Clin Sci 1982;63:393–6.PubMedGoogle Scholar
  7. [7]
    Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent histamine release from rabbit platelets: The role of IgE, basophils and a platelet-activating factor. J Exp Med 1972; 136:1356–77.CrossRefPubMedGoogle Scholar
  8. [8]
    Benveniste J. Paf-acether, an ether phospholipid with biological activity. Proc Clin Biol Res 1988;282:73.Google Scholar
  9. [9]
    Arnoux B, Joseph M, Simöes MH, Tonnel AB, Duroux P, Capron A, et al. Antigenic release of paf-acether and b-glucuronidase from alveolar macrophages of asthmatics. Bull Eur Physiopathol Resp 1987;23:119–24.Google Scholar
  10. [10]
    Hopp RJ, Bewta AK, Agrawal DK, Townley RG. Effect of platelet-activating factor inhalation on nonspecific bronchial hyperreactivity in man. Chest 1989;96:1070–2.PubMedGoogle Scholar
  11. [11]
    Goswami SK, Ohashi M, Stathas P, Marom ZM. Plateletactivating factor stimulates secretion of respiratory glycoconjugate from human airways in culture. J Allergy Clin Immunol 1989;84:726–34.CrossRefPubMedGoogle Scholar
  12. [12]
    Martin U, Römer D. The pharmacological properties of a new, orally active anti-anaphylacctic compound: Ketotifen, a benzocyclo-heptathiophene. Arzneim Forsch/Drug Res 1978; 28:770–82.Google Scholar
  13. [13]
    Arnoux B, Denjean A, Page CP, Nobile D, Morley J, Benveniste J. Accumulation of platelets and eosinophils in baboon lung after paf-acether challenge. (Inhibition by ketotifen). Am Rev Respir Dis 1988;137:855–60.PubMedGoogle Scholar
  14. [14]
    Devillier P, Arnoux B, Lalau Keraly C, Landes A, Marsac J, Benveniste J. Inhibition of human and rabbit platelet activation by ketotifen. Fundam Clin Pharmacol 1990;4:1–9.PubMedGoogle Scholar
  15. [15]
    Chevance LG, Lennon JF. Etude des rythmes des battements ciliaires. Acta Otolaryngol 1970;70:16–29.PubMedGoogle Scholar
  16. [16]
    Ganbo T, Hisamatsu K. Mucosal dysfunction and damage induced by platelet-activating factor (PAF). Acta Otolaryngol 1990;110:427–36.PubMedGoogle Scholar
  17. [17]
    Nieminen MM, Moilanen EK, Nyhlolm JEJ, Koshinen MO, Karvonen JI, Metsä-Keteldä TJ, et al. Platelet-activating factor impairs mucociliary transport and increases leucotriene B4 in man. Eur Respir J 1991;4:551–60.PubMedGoogle Scholar
  18. [18]
    Yukawa Y, Read RC, Kroegel C, Rutman A, Chung KF, Wilson R, et al. The effects of activated eosinophils an neutrophils on guinea-pig airway epithelium in vitro. Am J Respir Cell Mol Biol 1990;2:341–53.PubMedGoogle Scholar
  19. [19]
    Sturgess JM, Czegledy-Nagy E. Mucus-secretion in the lung. In: Johari O, editor. Scanning electron microscopy II. SEM Inc, AMF O'Hare, 1978:1083–6.Google Scholar
  20. [20]
    Muirhead EE, Byers LW, Desiderio D, Mith KA, Prewitt RL, Brooks B. Alkyl ether analogs of phosphatidylcholine are orally active in hypertensive rabbits. Hypertension 198;3: 107–11.Google Scholar
  21. [21]
    Hwang SB, Lam MH, Shen TY. Specific binding sites for platelet activating factor in human lung tissues. Biochem Biophys Res Commun 1985;128:972–9.PubMedGoogle Scholar
  22. [22]
    Handa RK, Strandhoy JW, Buckalew VM. Vasorelaxant effect of C16-paf and C18-paf on renal blood flow and systemic blood pressure in the anesthetized rat. Life Sci 1991;49:747–52.CrossRefPubMedGoogle Scholar
  23. [23]
    Haroldsen PE, Voelkel NF, Henson JE, Henson PM, Murphy RC. Metabolism of platelet-activating factor in isolated perfused rat lung. J Clin Invest 1987;1860–7.Google Scholar
  24. [24]
    Kumar R, King RJ, Martin HM, Hanahan DJ. Metabolism of platelet-activating factor (alkylacetylphosphorylcholine) by type-II epithelial cells and fibroblasts from rat lungs. Biochim Biophys Acta 1987;917:33–41.PubMedGoogle Scholar
  25. [25]
    Arnoux B, Duval D, Benveniste J. Release of platelet-activating factor (PAF-acether) from alveolar macrophage by the calcium ionophore A23187 and phagocytosisvest. Eur J Clin Invest 1980;10:437–41.PubMedGoogle Scholar
  26. [26]
    Mac-Donald GF, Ackerman F, Plumbley OL, editors. A double-blind study to clinically evaluate Ketotifen in the treatment of bronchial asthma. Proceedings of the symposium on Ketotifen. Recent advances in the treatment of asthma. Amsterdam: Excerpta Medica, 1988:47–57.Google Scholar
  27. [27]
    Okuda M. Clinical investigation of ketotifen in perennial allergic rhinitis: a double-blind comparative study of ketotifen and clemastine fumarate. Rhinology 1984;22:171–82.PubMedGoogle Scholar
  28. [28]
    Denjean A, Arnoux B, Masse R, Lockhart A, Benveniste J. Acute effect of intratracheal administration of platelet-activating factor in baboons. J Appl Physiol 1983;55:799–804.PubMedGoogle Scholar
  29. [29]
    Hoshiko K, Kristerson A, Morley J. Ketotifen inhibits exacerbation of allergic hyperreactivity by racemic salbutamol in the guinea pig. J Allergy Clin Immunol 1993;91:909–16.CrossRefPubMedGoogle Scholar
  30. [30]
    Iwama T, Nagai H, Tsuruoka N, Koda A. Effect of murine recombinant interleukin-5 on bronchial reactivity in guinea pig. Clin Exp Allergy 1993;23:32–8.PubMedGoogle Scholar
  31. [31]
    Howel RE, Sickels BD, Weichman BM. Comparison of the airway hyperreactivity produced by single and multiple antigen exposures in sensitized guinea pig. Agents Actions 1992;37: 195–7.CrossRefPubMedGoogle Scholar
  32. [32]
    Koshino T, Agrawal DK, Townley TA, Townley RG. Ketotifen prevents terbutaline-induced down-regulation of beta-adrenoceptors in guinea-pig lung. Biochem Biophys Res Commun 1988;2:1221–7.CrossRefGoogle Scholar
  33. [33]
    Brodde OE, Howe U, Egersszegi S, Konietzko N, Michel MC. Effect of prednisolone and ketotifen on beta2-adrenoceptors in asthmatic patients receiving beta2-bronchodilators. Eur J Clin Pharmacol 1988;34:145–50.CrossRefPubMedGoogle Scholar
  34. [34]
    Chand N, Pillar J, Diamantis W, Sofia RD. Inhibition of allergic histamine release by azelastine and selected antiallergic drugs from rabbit leukocytes. Int Arch Allergy Appl Immunol 1985;77:451–5.PubMedGoogle Scholar
  35. [35]
    Cuss FM, Dixon CMS, Barnes PJ. Effects of inhaled plateletactivating factor on pulmonary function and bronchial responsiveness in man. Lancet 1986;ii:189–92.CrossRefGoogle Scholar
  36. [36]
    O'Donnell SR, Barnett CJ. Microvascular leakage to platelet activating factor in guinea-pig trachea and bronchi. Eur J Pharmacol Physiol 1987;138:385–96.CrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag 1996

Authors and Affiliations

  • L. Kahhak
    • 1
  • A. Roche
    • 2
  • C. Dubray
    • 2
  • C. Arnoux
    • 1
  • J. Benveniste
    • 1
  1. 1.INSERM U 200ClamartFrance
  2. 2.Laboratoires SandozRueil Malmaison CedexFrance

Personalised recommendations